- Tempest Therapeutics CEO and President Matthew Angel reported an indirect purchase of 231,482 common shares at USD 2.16 per share.
- Following the reported transaction, he beneficially owned 4,837,070 common shares directly.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001931356-26-000011), on March 25, 2026, and is solely responsible for the information contained therein.